Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-679-9600
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees142
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions
What is Rubius Therapeutics' stock symbol?
Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."
How were Rubius Therapeutics' earnings last quarter?
Rubius Therapeutics Inc (NASDAQ:RUBY) released its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.04. During the same period last year, the company earned ($3.33) earnings per share. View Rubius Therapeutics' Earnings History.
When is Rubius Therapeutics' next earnings date?
What price target have analysts set for RUBY?
5 brokerages have issued twelve-month price targets for Rubius Therapeutics' stock. Their forecasts range from $4.00 to $40.00. On average, they anticipate Rubius Therapeutics' share price to reach $25.00 in the next year. This suggests a possible upside of 166.5% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics.
What is the consensus analysts' recommendation for Rubius Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rubius Therapeutics.
What are Wall Street analysts saying about Rubius Therapeutics stock?
Here are some recent quotes from research analysts about Rubius Therapeutics stock:
- 1. According to Zacks Investment Research, "Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States. " (7/24/2019)
- 2. HC Wainwright analysts commented, "We have currently only assigned value to RTX-134 in PKU and RTX-240 in NSCLC. Our price target of $40/share is based on an equally-weighted composite of: (a) $40.7/share, as a 30x multiple of taxed and diluted $21.95 discounted back to FY19 at 20% (in line with the expected P/E multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $39.4/share (discounted cash flow analysis using a 20% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (6/26/2019)
Has Rubius Therapeutics been receiving favorable news coverage?
Press coverage about RUBY stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Rubius Therapeutics earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Rubius Therapeutics.
Who are some of Rubius Therapeutics' key competitors?
Some companies that are related to Rubius Therapeutics include Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA), Regenxbio (RGNX), Denali Therapeutics (DNLI), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Aerie Pharmaceuticals (AERI) and Fate Therapeutics (FATE).
What other stocks do shareholders of Rubius Therapeutics own?
Who are Rubius Therapeutics' key executives?
Rubius Therapeutics' management team includes the folowing people:
- Mr. David R. Epstein, Exec. Chairman (Age 57)
- Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 63)
- Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 56)
- Mr. Andrew M. Oh, Chief Financial Officer (Age 47)
- Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 50)
When did Rubius Therapeutics IPO?
(RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.
How do I buy shares of Rubius Therapeutics?
Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Rubius Therapeutics' stock price today?
One share of RUBY stock can currently be purchased for approximately $9.38.
How big of a company is Rubius Therapeutics?
Rubius Therapeutics has a market capitalization of $747.13 million. The company earns $-89,190,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.View Additional Information About Rubius Therapeutics.
What is Rubius Therapeutics' official website?
How can I contact Rubius Therapeutics?
Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]
MarketBeat Community Rating for Rubius Therapeutics (NASDAQ RUBY)
MarketBeat's community ratings are surveys of what our community members think about Rubius Therapeutics and other stocks. Vote "Outperform" if you believe RUBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RUBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
